@article{10608,
  keywords = {DPP4 inhibitor, SGLT2 inhibitor, diabetes complications, Observational study, population study, Type 2 diabetes},
  author = {I. Idris and R. Zhang and J. Mamza and M. Ford and T. Morris and A. Banerjee and K. Khunti},
  title = {Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting},
  year = {2022},
  journal = {Diabetes Obes Metab},
  edition = {2022/06/10},
  isbn = {1462-8902},
  doi = {10.1111/dom.14799},
  note = {1463-1326
Idris, Iskandar
Zhang, Ruiqi
Mamza, Jil B
Ford, Mike
Morris, Tamsin
Banerjee, Amitava
Khunti, Kamlesh
Orcid: 0000-0003-2343-7099
AstraZeneca/
Horizon 2020/
European Union/
Innovative Medicines Initiative/
UK Research and Innovation/
the British Medical Association/
National Institute for Health and Care Research/
Biomedical Research Centre/
National Institute for Health Research/
Merck Sharp & Dohme/
Novo Nordisk/
Boehringer Ingelheim/
DH_/Department of Health/United Kingdom
Journal Article
England
Diabetes Obes Metab. 2022 Jun 8. doi: 10.1111/dom.14799.},
  language = {eng},
}